Novartis loses Indian Glivec case
This article was originally published in Scrip
India's Supreme Court has dismissed Novartis' plea in the crucial case concerning its anticancer Glivec (imatinib mesylate) and the interpretation of the controversial Section 3(d) provision of India's patent law.
You may also be interested in...
Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.